Legend Biotech : 2025 Legend Corporate Presentation

Published: 2025-01-14 23:05:04 ET LEGN

Legend Biotech

CORPORATE PRESENTATION

JANUARY 14, 2025

Legend Biotech - Transforming Cancer Care

Pioneer

2,500+

11 Pipeline

and Leader in

Employees

Programs

CAR-T Therapy

450+ Focused

in Hematologic

Revolution

on R&D

Malignancies, Solid Tumors,

and Autoimmune Diseases

Stand-alone

Partnerships

$1.2B

with

Johnson & Johnson

in Cash, Cash Equivalents and

End-to-end

Time Deposits1

And

Capabilities

Novartis

: LEGN

3 1. As of September 30, 2024

CARVYKTI®

Proven Leader on the Path to Cure

First and only CAR-T cell therapy providing superior OS vs SoC in Multiple Myeloma

>4,500 treated patients treated

Significant sales growth trajectory, strong 2L+ launch with the OS benefit achieved

Strongest CAR-Tlaunch to date, with $286M in net trade sales in 3Q24

Outpatient commercial advantage (48% out-patient use in 3Q24)

Multiple Myeloma

Blood Cancer with a High Unmet Need

POOR SURVIVAL OUTCOMES IN

MULTIPLE REFRACTORY MM

Median OS < 12 months

in patients refractory to anti-CD38, ≥ 1 PI(s)

and / or ≥ 1 IMiD(s)6

3RD MOST COMMON BLOOD CANCER

accounting for 14% of all hematologic cancer1

187,952

NEW CASES WORLDWIDE IN 20221,2

Proportion Surviving

Median OS for each group

Median OS

(months)

95% Cl

1.0

Non-triple-refractory

11.2

(5.4-17.1)

0.8

Triple-and quad-refractory

9.2

(7.1-11.2)

0.6

Penta-refractory

5.6

(3.5-7.8)

0.4

Non-triple-refractory (N=57)

0.2

P=0.002

Triple-and quad-refractory (N=148)

0.0

Penta-refractory (N=70)

20 Months 30

CI, confidence interval; PI, Proteasome Inhibitor; IMiD, immunomodulatory drug; MM, multiple myeloma; OS, overall survival

1. Globocan 2022 World Fact Sheet: https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf. Accessed March 2024. 2. Globocan 2022 World Fact Sheet: World. 5 https://gco.iarc.who.int/media/globocan/factsheets/cancers/35-multiple-myeloma-fact-sheet.pdf. Accessed March 2024.

Legend and J&J Global Collaboration

Worldwide Collaboration and License Agreement to Develop and Commercialize Cilta-cel with J&J, the #1 Global Multiple Myeloma Market Leader

50/50

Europe

United States

50/50

Japan

Working Together to Realize CARVYKTI'S $5B+ Potential

CARVYKTI® - First CAR-T in MM to Achieve OS Benefit vs SOC

Gold Standard for Oncology Trials

CARVYKTI® Significantly Improved OS vs SOC1

Median follow-up 33.6 months

100

30-month OS

76.4%

CARVYKTI®

alive

63.8%

SOC

HR (95% CI): 0.55 (0.39-0.79); P=0.0009

9 12 15 18 21 24 27 30 33 36 39 42 45

Months

1. Mateos, et al. Overall Survival (OS) With Ciltacabtagene Autoleucel (Cilta-cel) Versus Standard of Care (SoC) in Lenalidomide (Len)-Refractory Multiple Myeloma (MM): Phase 3 CARTITUDE-4 Study Update. International Myeloma Society 2024 Annual Meeting. September 2024.

7 2. San-Miguel J, et al. N Engl J Med 2023;389:335-47. OS: overall survival; PFS: progression-free survival; SOC: standard of care; MM: multiple myeloma; LOT: line(s) of therapy; MNT: movement and neurocognitive treatment-emergent adverse event

MAXIMIZING OUR CARVYKTI MARKET LEADERSHIP

A New Standard for CAR-T Launches

C A R V Y K T I ® - INDUSTRY LEADING EARLY

FIRST TEN QUARTERS OUTPERFORMING

LAUNCH PERFORMANCE

HISTORICAL CAR - T LAUNCHES

Quarterly sales ($MM)

450

400

350

300

250

200

150

100

WORLDWIDE SALES OF CAR-T THERAPIES, BY QUARTER OF LAUNCH (IN $MM)

Carvykti

Kymriah

Yescarta

Tecartus

Breyanzi

Abecma

387

286

224

124

102

Q10 Q11 Q12 Q13 Q14 Q15 Q16 Q17 Q18 Q19 Q20 Q21 Q22 Q23 Q24 Q25 Q26 Q27 Q28

Quarters since launch

9 Data Source: Companies' public filings.

CARVYKTI® Uptake Continues

Continued Market Penetration and Earlier Lines of Treatment Represents Significant Opportunity for Continued Growth

300

250

200

150

100

CARVYKTI® Net Trade Sales ($MM)

+88% growth vs Q3'23

258

12 13 16 167

3 146 140

114

140

2022

2023

2024

U.S.

OUS

YoY Growth1

QoQ Growth2

U.S.

84%

54%

OUS

125%

35%

Global

88%

53%

1. Q3 2024 vs Q3 2023

2. Q3 2024 vs Q2 2024

Earlier Line Studies

Another Opportunity to Change the Treatment Paradigm

CARTITUDE-21

CARTITUDE-52

CARTITUDE-63

NCT04133636

NCT04923893

NCT05257083

• Global, multi-cohort study

• Global, randomized, registrational

• Phase II open-label study of cilta-

study

cel in various clinical settings

• Phase III open-label study of VRd

• Phase III open-label study comparing

• Active, Not Recruiting

followed by cilta-cel vs. VRd followed

DVRd followed by cilta-cel vs. DVRd

by Rd maintenance, in patients with

followed by ASCT in NDMM patients

NDMM for whom ASCT is not planned

who are transplant eligible

as initial therapy

• Enrolling

• Enrollment completed

ASCT, autologous stem cell transplant; DVRd, daratumumab, bortezomib, lenalidomide, dexamethasone; NDMM, newly diagnosed multiple myeloma; VRd, bortezomib, lenalidomide, dexamethasone. 1. Clinicaltrials.gov: NCT04133636. 2. Clinicaltrials.gov: NCT04923893. 3. Clinicaltrials.gov: NCT05257083. CARTITUDE-6 is a collaborative study sponsored by the European Myeloma Network.

Disclaimer

Legend Biotech Corporation published this content on January 15, 2025, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on January 15, 2025 at 04:04:04.565.